HbA1c could be useful in assessing individuals at risk of developing cystic fibrosis-related diabetes

  • Choudhury M & al.
  • Diabet Med
  • 30 Jan 2019

  • curated by Sarfaroj Khan
  • UK Clinical Digest
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • This study identifies a link between HbA1c level and the future development of dysglycaemia in cystic fibrosis (CF) based on oral glucose tolerance test (OGTT), as well as microvascular outcomes

Why this matters

  • Although current guidance does not advocate the use of HbA1c as a diagnostic tool in cystic fibrosis-related diabetes (CFRD), it may be of clinical use in determining individuals at risk of future development of CFRD.

Study design

  • This 7-year retrospective longitudinal study compared OGTT results with HbA1c measurements to predict CFRD risk in 50 adult patients with CF.
  • Retinal screening data were compared with HbA1c measurements to evaluate microvascular outcomes.
  • Funding: None.

Key results

  • Of 50 patients with CF, 18 had HbA1c level of
  • During the follow-up period, 4 patients with an HbA1c level of
  • Patients with HbA1c level of ≥37 mmol/mol (5.5%) were significantly more likely to develop abnormal OGTT over a 7-year period (HR, 3.49; 95% CI, 1.5-8.1).
  • Severe form of diabetic retinopathy was associated with higher HbA1c level (P=.038) and longer duration of CFRD risk (>5 years).

Limitations

  • Small population size.
  • Study did not measure haematological variables.

Please confirm your acceptance

To gain full access to GPnotebook please confirm:

By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.

Submit